Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Condition(s) studied
Investigational drug(s) / intervention(s)
JX10: JX10 is a thrombolytic agent.
Placebo: Placebo is being used as the comparator.
Study summary
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.
The main question the study aims to answer are:
1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS.
2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.
During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.
Eligibility
Primary outcome measure(s)
- Efficacy: Proportion of participants with no or minimal symptoms (mRS score 0-1) at 90 days — 90 days
- Safety: Incidence of symptomatic intracranial hemorrhage within 36 hours post-randomization — Within 36 hours post-randomization
Trial sites (104)
| Facility | City | Region | Status |
|---|---|---|---|
| Corxel Investigational Site | Long Beach | California | Recruiting |
| Corxel Investigational Site | Los Angeles | California | Recruiting |
| Corxel Investigational Site | Sacramento | California | Recruiting |
| Corxel Investigational Site | Colorado Springs | Colorado | Recruiting |
| Corxel Investigational Site | Washington D.C. | District of Columbia | Recruiting |
| Corxel Investigational Site | Delray Beach | Florida | Recruiting |
| Corxel Investigational Site | Chicago | Illinois | Recruiting |
| Corxel Investigational Site | Wichita | Kansas | Recruiting |
| Corxel Investigational Site | Baltimore | Maryland | Recruiting |
| Corxel Investigational Site | Kalamazoo | Michigan | Recruiting |
| Corxel Investigational Site | Traverse City | Michigan | Recruiting |
| Corxel Investigational Site | St Louis | Missouri | Recruiting |
| Corxel Investigational Site | Great Neck | New York | Recruiting |
| Corxel Investigational Site | New York | New York | Recruiting |
| Corxel Investigational Site | Columbus | Ohio | Recruiting |
| Corxel Investigational Site | Toledo | Ohio | Recruiting |
| Corxel Investigational Site | Tulsa | Oklahoma | Recruiting |
| Corxel Investigational Site | Chattanooga | Tennessee | Recruiting |
| Corxel Investigational Site | Dallas | Texas | Recruiting |
| Corxel Investigational Site | Houston | Texas | Recruiting |
| Corxel Investigational Site | Ghent | Belgium | Recruiting |
| Corxel Investigational Site | Hasselt | Belgium | Recruiting |
| Corxel Investigational Site | Blagoevgrad | Bulgaria | Recruiting |
| Corxel Investigational Site | Burgas | Bulgaria | Recruiting |
| Corxel Investigational Site | Pleven | Bulgaria | Recruiting |
| Corxel Investigational Site | Plovdiv | Bulgaria | Recruiting |
| Corxel Investigational Site | Sofia | Bulgaria | Recruiting |
| Corxel Investigational Site | Edmonton | Canada | Recruiting |
| Corxel Investigational Site | Kingston | Canada | Recruiting |
| Corxel Investigational Site | Winnipeg | Canada | Recruiting |
| Corxel Investigational Site | Baotou | China | Recruiting |
| Corxel Investigational Site | Beijing | China | Recruiting |
| Corxel Investigational Site | Beijing | China | Recruiting |
| Corxel Investigational Site | Changchun | China | Recruiting |
| Corxel Investigational Site | Guangzhou | China | Recruiting |
| Corxel Investigational Site, | Harbin | China | Recruiting |
| Corxel Investigational Site | Harbin | China | Recruiting |
| Corxel Investigational Site | Kaili | China | Recruiting |
| Corxel Investigational Site | Linfen | China | Recruiting |
| Corxel Investigational Site | Nanyang | China | Recruiting |
+ 64 more sites — see the full list on the official registry below.
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06990867 on ClinicalTrials.gov ↗ ← All trials in Italy